These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36592300)

  • 21. SOTYKTU
    Gupta AK; Wang T; Vincent K; Abramovits W
    Skinmed; 2023; 21(3):192-196. PubMed ID: 37634105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
    Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
    Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
    Jensen LT; Attfield KE; Feldmann M; Fugger L
    EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2024 Dec; 35(1):2307489. PubMed ID: 38305215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deucravacitinib for the Treatment of Psoriatic Disease.
    Lé AM; Puig L; Torres T
    Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
    Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
    J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
    Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
    Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
    J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature.
    Potestio L; Ruggiero A; Fabbrocini G; Martora F; Megna M
    Psoriasis (Auckl); 2023; 13():19-26. PubMed ID: 37168605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
    Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
    J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
    Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
    J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
    Wang J; Batista VS; Bunick CG
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
    Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
    Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.
    Catlett IM; Aras U; Hansen L; Liu Y; Bei D; Girgis IG; Murthy B
    Clin Transl Sci; 2023 Jan; 16(1):151-164. PubMed ID: 36325947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
    Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
    Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis.
    Zheng Y; Han Y; Chen J; Huang J; Zhu C; Lin L; Su H
    Indian J Dermatol Venereol Leprol; 2024; 90(5):590-598. PubMed ID: 38899421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
    Fang Z; Sun H; Wang Y; Sun Z; Yin M
    Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.